top of page
Gregory MacMichael - cropped.jpeg
  • LinkedIn

Gregory J. MacMichael, Ph.D.

Cell and Gene Therapy Development. 

Career Highlights

  • Over 35 years of biopharmaceutical experience in developing and manufacturing of biologics, vaccines and cell and gene therapies.

  • President of CMC Bioservices, a consultancy focused on the development and manufacturing of cell and gene therapies, biologics, and vaccines.

  • Greg has worked with a variety of notable companies including Novartis, Wyeth, Eli Lilly, Chiron, Centocor and Cook.  

  • At Novartis, he led the development of the drug substance and drug product processes for numerous monoclonal antibodies and therapeutic proteins.  In addition, Greg was a core member of Novartis’s leadership team and led the CMC efforts with respect to the acquisition of CART19 (Kymriah) from the University of Pennsylvania.  

  • Vice President and CSO for two years at Cook Pharmica.  

  • Vice President of Vaccine Development at Wyeth, where he was instrumental in the development of Prevnar, Prevnar 13 and CAIV (Cold Adapted Influenza Vaccine).

  • At Eli Lilly, Greg led the development and commercialization of Xigris (Activated Protein C produced in HEK293 cells) and Forteo (parathyroid hormone produced in E. coli).  

  • At Chiron, he developed and produced multiple recombinant vaccines produced in CHO cells, and his efforts at Centocor contributed to the development of the monoclonal antibodies Remicade, ReoPro and Centoxin. 


  • Doctor of Philosophy in Microbiology/Biochemistry from Mississippi State University

  • Master of Science in Microbiology/Biochemistry from North Carolina State University

  • BS in Microbiology from Pennsylvania State University.

bottom of page